BCNI Clinical Trials

See our short film which gives one Irish patient's experience on a clinical trial and gives an overview of clinical trials by Prof Michael O'Dwyer, Director of Blood Cancer Newtork Ireland

BCNI will carry out early phase clinical trials in cancer care centres in Galway, Cork and Dublin. Clinical trials are designed to develop and test new and improved ways to treat cancer in people; help prevent a return of cancer; and improve comfort and quality of life for people with cancer. Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies. BCNI trials will focus on novel targeted approaches, including immunotherapy.

Please see here for  Patient information leaflet -Clinical trials

Clinical trials are designed to develop and test new and improved therapies

New therapies are usually developed and tested in a laboratory. Then they are thoroughly tested in animals. If the early research (the preclinical trials) shows the therapy is safe and effective, a carefully planned and monitored clinical trial of the drug or treatment will then be conducted in people. 

 

‌ 

Advances in treatments for blood cancers depend on clinical trials of new therapies or new combinations of therapies.

  • The BCNI will carry out early phase clinical trials in cancer care centres in strategic geographical locations (Galway, Cork & Dublin) under a single unified structure.  

  • This will be led by University Hospital Galway, which has well established early phase trial expertise for blood cancers and phase I capability will be rapidly extended to the other centres (St James’s Hospital, Mercy University Hospital, Cork University Hospital, Beaumont hospital and the Mater hospital).

  • The cohesive and national structure of the BCNI will make Ireland an attractive place for industry and clinical researchers to carry out their clinical trials. The main advantage of this is that it will provide Irish patients with easier access to novel experimental drugs and provide them with a very high level of care and attention.

 

ACTIVE CLINICAL TRIALS

Please see below for our clinical trials that are currently OPEN

Multiple Myeloma
Study Title
Patient Population
BCNI Sites 
ClinicalTrials.gov link for further study info
Study Contacts
GMI-1271-201 - A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma Relapsed/Refractory Multiple Myeloma

Galway University Hospital - OPEN AND RECRUTING

Beaumont Hospital-OPEN AND RECRUTING

Cork University Hospital- OPEN AND RECRUTING

GMI1271-230

GUH: Jessica Walsh +353 (0)91-494099

Beaumont Hospital: Tara Kenny +353 (0)18 09 2080

Cork University Hospital: Contact:Elizabeth Linehan +353 (0)21 49 20052 

Multiple Myeloma 
Study Title
Patient Population
BCNI Sites
ClinicalTrials.gov link for further study info
Study Contacts
CyBorD-DARA Phase Ib study of weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) withDaratumumab (DARA) in transplant eligible patientswith newly diagnosed Multiple Myeloma (MM). “TheCyBorD-DARA study” Newly Diagnosed Multiple Myeloma

Opened at Galway University Hospital and Cork University Hospital and Beaumont..  RECRUITMENT NOW CLOSED

 

CyBorD-Dara

GUH:PI: Professor Michael O’Dwyer                      Contact: Jessica Walsh +353(0(91 494099

Cork University Hospital:PI: Professor Mary Cahill Contact:Debra O’Hare+353 (0)21 49 20051 

Beaumont:PI: Dr. John Quinn Contact:Tara Kenny +353 (0)18 09 2080 

 

See video of Prof Michael O'Dwyer talk about the CyBorD-DARA study at the American Society of Hematology meeting 2017 in Atlanta

 
 

UPCOMING CLINICAL TRIALS

 GMI 1271-301

Study Title
Patient Population
BCNI Sites 
ClinicalTrials.gov link for further study info
Study Contacts
GMI1271-301 A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia  Adults with relapsed/refractory acute myeloid leukemia (AML) 

Galway University Hospital (confirmed) and potentially other BCNI sites in Cork and Dublin

Aim to open study in Q1  2019

 

Not available yet

GUH: Jessica Walsh +353 (0)91-494099

Clinical Trials - now closed

BCNI Clinical trials that are now CLOSED

Acute Myeloid Leukemia
Study Title
Patient Population
BCNI Sites 
ClinicalTrials.gov link for further study info
Study Contacts
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
  1. Age >18y/o Relapsed/Refractory AML
2. Age >60y/o newly diagnosed AML
Galway University Hospital GMI1271-201 GUH: PI Michael O'Dwyer Contact :Jessica Walsh +353(0)91-494099